Research

Hormonal

Subcutaneous self-administration of oxyntomodulin (400 nmol, three times daily, 30 minutes before meals) for 4 weeks significantly reduces body weight in overweight and obese subjects by reducing energy intake without altering subjective food palatability.

For overweight or obese individuals, a 4-week trial of subcutaneous oxyntomodulin (400 nmol, 3x daily before meals) can lead to significant weight loss (~2.3 kg) by reducing food intake without making food taste worse. While injections are required and nausea is a potential side effect (manageable by dose adjustment), compliance was high in this study. This suggests that mimicking natural satiety hormones is a viable, specific anti-obesity strategy compared to broader neurotransmitter drugs.

GoodSupportsHIGH confidence
Self-administering oxyntomodulin subcutaneously effectively reduced body weight by 2.4% over a 4-week period in healthy overweight and obese volunteers... A significant reduction in energy intake with preservation of subjective food palatability was also observed.
Katie Wynne et al. · Diabetes · 2005

Why this rating

Double-blind, randomized, controlled trial with statistically significant results (P < 0.01), though limited by small sample size (n=26) and short duration (4 weeks).

Source

Subcutaneous Oxyntomodulin Reduces Body Weight in Overweight and Obese Subjects

Katie Wynne et al. · Diabetes · 2005

DOI 10.2337/diabetes.54.8.2390

rct · n=26Cited 431×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →